Shinpoong Pharmaceutical to supply anti-adhesion agent to South Africa

Shinpoong Pharmaceutical said it has signed a contract with Cossni Medical, a South African medical device company, to supply Medicurtain, its anti-adhesion drug used in surgery.

Under the contract, Shinpoong will supply $7.97 million (approximately 10.6 billion won) worth of Medicurtain to Cossni Medical, and the latter will be solely responsible for distribution and sales in three countries, including South Africa, Namibia, and Botswana.

Anti-adhesion agents are widely used in abdominal surgery and hysteroscopic surgery to prevent skin or membranes from sticking due to inflammation after surgery.

Shinpoong’s product has additional effects, such as inflammation suppression, as it minimizes the degree of adhesion, the intensity of adhesion, and the area of adhesion, by using high molecular weight and high viscosity hyaluronic acid and hydroxyethyl starch.

The Korean company has also obtained CE (Conformité Européenne) certification from the European Union (EU), indicating that it meets the European standards related to safety, health, and environmental protection required for import and export between EU member states.

“Medicurtain is an effective anti-adhesion agent that has obtained CE certification, and we expect its growth in overseas markets to accelerate rapidly,” a Shinpoong official said.